100 related articles for article (PubMed ID: 16417523)
1. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants.
Loo TW; Bartlett MC; Wang Y; Clarke DM
Biochem J; 2006 May; 395(3):537-42. PubMed ID: 16417523
[TBL] [Abstract][Full Text] [Related]
2. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
Wang Y; Bartlett MC; Loo TW; Clarke DM
Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
[TBL] [Abstract][Full Text] [Related]
3. Correctors promote folding of the CFTR in the endoplasmic reticulum.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
[TBL] [Abstract][Full Text] [Related]
4. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
Loo TW; Bartlett MC; Clarke DM
Mol Pharm; 2005; 2(5):407-13. PubMed ID: 16196493
[TBL] [Abstract][Full Text] [Related]
5. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.
Cormet-Boyaka E; Jablonsky M; Naren AP; Jackson PL; Muccio DD; Kirk KL
Proc Natl Acad Sci U S A; 2004 May; 101(21):8221-6. PubMed ID: 15141088
[TBL] [Abstract][Full Text] [Related]
6. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
[TBL] [Abstract][Full Text] [Related]
7. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Bartlett MC; Loo TW; Clarke DM
J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010
[TBL] [Abstract][Full Text] [Related]
8. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
[TBL] [Abstract][Full Text] [Related]
9. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
10. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine.
Robert R; Carlile GW; Liao J; Balghi H; Lesimple P; Liu N; Kus B; Rotin D; Wilke M; de Jonge HR; Scholte BJ; Thomas DY; Hanrahan JW
Mol Pharmacol; 2010 Jun; 77(6):922-30. PubMed ID: 20200141
[TBL] [Abstract][Full Text] [Related]
11. Functional cystic fibrosis transmembrane conductance regulator tagged with an epitope of the vesicular stomatis virus glycoprotein can be addressed to the apical domain of polarized cells.
Costa de Beauregard MA; Edelman A; Chesnoy-Marchais D; Tondelier D; Lapillonne A; El Marjou F; Robine S; Louvard D
Eur J Cell Biol; 2000 Nov; 79(11):795-802. PubMed ID: 11139142
[TBL] [Abstract][Full Text] [Related]
12. Repair of CFTR folding defects with correctors that function as pharmacological chaperones.
Loo TW; Clarke DM
Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776
[TBL] [Abstract][Full Text] [Related]
13. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
14. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
15. Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel.
Seibert FS; Jia Y; Mathews CJ; Hanrahan JW; Riordan JR; Loo TW; Clarke DM
Biochemistry; 1997 Sep; 36(39):11966-74. PubMed ID: 9305991
[TBL] [Abstract][Full Text] [Related]
16. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
Loo TW; Clarke DM
Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
[TBL] [Abstract][Full Text] [Related]
17. Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump.
Loo TW; Bartlett MC; Shi L; Clarke DM
Biochem Pharmacol; 2012 Feb; 83(3):345-54. PubMed ID: 22138447
[TBL] [Abstract][Full Text] [Related]
18. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
Namkung W; Kim KH; Lee MG
Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
[TBL] [Abstract][Full Text] [Related]
19. Rescue of folding defects in ABC transporters using pharmacological chaperones.
Loo TW; Bartlett MC; Clarke DM
J Bioenerg Biomembr; 2005 Dec; 37(6):501-7. PubMed ID: 16691490
[TBL] [Abstract][Full Text] [Related]
20. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
Loo TW; Bartlett MC; Clarke DM
Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
